Complete clinical trials solution company, Hawthorne Effect, announced today (October 10) it had successfully recruited more than 1,000 patients in 48 states plus Hawaii for a study to qualify the prevalence of valvular heart disease (VHD).
A company says it is developing a small molecule drug without major safety issues to treat a growing number of cases of atrial fibrillation, the most common cardiac arrhythmia.
Positive data from a phase 2 clinical trial has proven the general mechanism of action of SK channel inhibition for treatment of atrial fibrillation (AF), an abnormal heart rhythm.
Digital enrollment for Lark Health’s Cardiovascular Disease DCT is sped up by using the “tapestry of the entire internet” through Curavit and 1nHealth.
The physIQ monitoring platform will be used to evaluate an inhaled treatment, developed by InCarda, that is intended to treat atrial fibrillation patients.
The company is joining with the Thrombosis Research Institute on the creation of a heart disease patient dataset to advance precision medicine development.
The Heart of Athletes study, using Deloitte’s ConvergeHealth MyPath for Clinical platform, aims to examine heart inflammation in athletes with the virus.
The BiovitalsHF, from Biofourmis, is intended to augment decision-making in clinical environments, and to supplement traditional pharmaceutical therapies.
A recent study indicates patients taking the cholesterol-lowering drugs prior to COVID hospitalization are far less likely to die as a result of the virus.
The American Heart Association’s Heart of Communicating Science modules are designed to help experts break complex talk into easy-to-understand language.
The pharma firm and health association plan to collaborate in order to help drive global action toward prevention and control of cardiovascular disease.
Medable joins the AHA’s ‘Innovators Network’ to develop the Human Heart Digitome, which is expected to be the largest real-world database dedicated to advancing cardiovascular disease research and patient care, says CEO.
Notocord, an Instem company, will provide data acquisition and analysis services to a research and innovation program to improve risk prediction of cardiovascular adverse events.
Novartis exercises its option to license Ionis’ RNA-targeting cardiovascular drug, adding to its cardiovascular treatment portfolio, as Entresto reaches the three-year mark on its patent.
